Company intelligence / Profile preview
Cellective BioTherapy, Inc.
Chapel Hill / Durham, North Carolina, United Statescellectivebiotherapy.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Cellective BioTherapy developed proprietary cellular and monoclonal antibody-based platforms targeting unique aspects of regulatory B cell biology to treat cancers, autoimmune conditions, and immunodeficiencies. The company focused on expanding human regulatory B cells ex vivo for autologous cellular immunotherapy as well as depleting pathogenic B cell subsets in vivo. No published clinical results are available; the company remained at an early/preclinical stage.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Cellular therapies (B cell-based)Monoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Cellective BioTherapy, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cellective BioTherapy, Inc..